Scientists use AI algorithm to better predict unknown tumor origins

English Español Français العربية Русский

RSS Newsletters

Radio TV

LANGUAGE
English Español Français العربية Русский Documentary CCTV+

Radio TV

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.

I agree

Translating...

Content is automatically generated by Microsoft Azure Translator Text API. CGTN is not responsible for any of the translations.

/CFP

A team of Chinese scientists have designed an artificial intelligence (AI) tool that predicts hard-to-identify tumor origins with an accuracy rivaling or even surpassing human pathologists.

Cancer of unknown primary (CUP) site poses challenges to clinicians due to its elusive nature. The CUP, which accounts for 3 percent to 5 percent of all cancers diagnosed in humans, tends to be malignant, with only 20 percent of CUP patients achieving a median survival of 10 months.

Screenshot of the study published in the journal Nature Medicine. /nature.com

The researchers, led by those from Tianjin Medical University and the First Affiliated Hospital of Zhengzhou University, developed a deep-learning method for tumor origin differentiation, trained via cytological images from 57,220 cases at four Chinese hospitals.

The tool called TORCH can identify malignant tumors in fluids accumulated in chest and abdomen and predict their origins, according to the study published this week in the journal Nature Medicine.

TORCH achieved a prediction accuracy for primary tumor origins of 82.6 percent, significantly improving the diagnostic scores compared with four human pathologists, according to the study.

Also, the treatment protocol given in accordance with TORCH-predicted origins resulted in an overall survival of 27 months compared to 17 months for those who received discordant treatment.

The study highlighted the AI system's potential as a valuable ancillary tool in clinical practice, although further validation in randomized trials is required, said the researchers.

Source(s): Xinhua News Agency